This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Pulmicort HFA-pMDI
Description: Pulmicort HFA-pMDI is a pressurized Metered-Dose inhaler (MDI) version of Pulmicort. The Metered Dose aerosol Inhaler uses a hydrofluoroalkane (HFA) propellant, replacing the chlorofluorocarbon (CFC) propellant used in the original version of Pulmicort. Pulmicort HFA-MDI incorporates proprietary SkyePharma formulation technology for delivery that matches the release profile of the current version of Pulmicort MDI.
Deal Structure: SkyePharma PLC signed exclusive agreements in December 2001 with AstraZeneca PLC to developthe next generation of AstraZeneca's Pulmicort Metered Dose Inhaler (MDI).
Under the terms of agreements, SkyePharma is responsible for all pre-clinical and clinical development of Pulmicort HFA-MDI, as well as compiling regulatory filings for marketing approval in Europe. AstraZeneca will pursue filing of the marketing application and following approval will market Pulmicort HFA-MDI in Europe and other non-US territories. AstraZeneca is responsible for the commercial supply of the product.
SkyePharma will receive a signing fee of US$2 million as well as progress-related milestone payments that could total up to US$10 million. In addition, SkyePharma earns a mid-teens royalty on AstraZenecas net sales of Pulmicort HFA-MDI.
SkyePharma and Vectura
In March 2016, the Boards of Skyepharma and Vectura announced that they had reached agreement regarding the terms of a...See full deal structure in Biomedtracker
Partners: Vectura Group
Pulmicort HFA-pMDI News
Pink Sheet Pulmicort generics on hold for a year
Additional information available to subscribers only: